跳至主要内容
临床试验/NCT07282028
NCT07282028招募中2 期

A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy

Nuance Hearing1 个研究点 分布在 1 个国家目标入组 89 人开始时间: 2025年7月27日最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
89
试验地点
1
主要终点
Spectacle Hearing Aid effectiveness

研究概览

简要总结

Following informed consent signature and upon verification of eligibility and execution of informed consent, subjects will be assigned a study code. The study comprises two groups. Screening visit will be conducted for both groups and include hearing test battery to assess hearing aid safety and efficacy

详细描述

Screening Written informed consent must be obtained for each study subject prior to the commencement of the study. Upon verification of eligibility and execution of informed consent, subjects will be assigned a study code.

The study comprises two groups, stage 1 will include up to 30 participants. Stage 2 will include up to 29 participants. Stage 1 will be conducted before Stage 2, and individuals enrolled in Stage 1 will not be eligible to participate in Stage 2. The eligibility criteria for each group are outlined below.

Screening procedures include:

  • ICF signature and process
  • Eligibility Assessment
  • Data collection: such as Age, Gender, demographic, ENT medical History
  • Otoscopy performed by ENT physician
  • Audiometry (Air conduction and bone conduction thresholds) might be performed as part of any other test day.
  • Spectacle Hearing Aid calibration and Fitting (this activity is subjected to test with Spectacle Hearing Aid ).
  • REM, aided only (optional) might be performed as part of any other test day.
  • Optometrist- for glasses prescription (stage 2 only) Stage 1 :This stage involves hearing evaluation tests , which will be conducted over up to four visits, depending on participant cooperation. Each visit will be scheduled on consecutive days or up to 3 weeks apart, based on the participant's and study staff availability.

Stage 2 : After completing the screening visit, each participant will attend two additional visits. At the enrollment visit, participants will receive their Spectacle Hearing Aid along with the prescribed lenses. They will undergo training using the device and will be asked to fill out questionnaires and performed hearing tests. Additionally, the device application and Electronic Patient-Reported Outcome (ePRO) will be installed on the participants' smartphones, and a demonstration will be provided. Participants will then be required to complete the ePRO daily until the study concludes. Functional auditory test battery will be conducted. Few weeks later, participants will return to complete questionnaires.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults aged 18 years and older
  • Perceived mild to moderate hearing loss as indicated by at least 1 positive answer to any of the signs specified by FDA: a) You have trouble hearing speech in noisy places, b) You find it hard to follow speech in groups, c) You have trouble hearing on the phone. d) Listening makes youtired, e) You need to turn up the volume on the TV or radio, and other people complain it's too loud
  • Wearing corrective glasses for daily use
  • Cognitive ability to understand and follow study instructions.
  • The main language used in social interactions is Hebrew
  • Participants must be willing to use the investigational device according to the instructions for use during the study period
  • Participants must be able to use a smartphone

排除标准

  • Hearing loss >55 dB HL
  • Prior hearing aid usages for the last 12 months
  • Medical history of cognitive or neurological impairment.
  • Active inflammatory conditions affecting the ear
  • Asymmetric or unilateral hearing loss - more than 15dB between ears in PTA4- based on screening or hearing test from the last 18 months.
  • participation in stage 1 study
  • Congenital ear defect or a deformed or injured ear
  • In the past 6 months discharge of blood, pus or fluid
  • Wax that might disturb REM test
  • Sudden hearing loss in the past 6 months
  • Wearer of electromagnetic medical device
  • Other medical conditions/medications that would interfere with subject safety or data collection in the opinion of the PI

结局指标

主要结局

Spectacle Hearing Aid effectiveness

时间窗: 2 weeks

Difference in SNR-50 when performed unaided versus aided using Spectacle Hearing Aid

Spectacle Hearing Aid safety

时间窗: 2 weeks

Incidence of device or procedure related adverse events

次要结局

未报告次要终点

研究者

发起方
Nuance Hearing
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

招募中
2 期
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics
NCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72
招募中
2 期
CO43923 Master Protocol: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substudy 1: A Study to Collect Patient-Level Data in Patients with Multiple Myeloma CO43923 Substudy 2 Cevos + Len Treatment: A Study Evaluating the Safety and Efficacy of Cevostamab in Combination with Lenalidomide in Patients with Cytogenetic High-Risk Features Receiving Maintenance Treatment After First Response from Multiple Myeloma Post-Stem Cell Transplant CO43923 Substudy 4 Cevostamab+ Iberdomide Treatment: A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Combination with Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
2023-504484-16-00F. Hoffmann-La Roche AG32
招募中
1 期
BY002 IIT Study in R/R Acute LeukemiaAcute Leukemia
NCT07270770The First Affiliated Hospital of Soochow University18
招募中
1 期
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsUnresectable Locally Advanced or Metastatic Urinary Tract Tumors
NCT07280832Shanghai JMT-Bio Inc.500
招募中
2 期
Patient Preference for Route of Administration with Intravenous Infusion Switch to Subcutaneous I-O Regimens in MelanomaMelanoma
2023-504515-33-00Bristol-Myers Squibb Services Unlimited Company82